SIMID First European Provider of Online Full Text Publications

SIMID is the first in Europe to use a single centralized databank to bring scientific-medical full-text publications within easy reach. Through S.M.I.L.E. (Scientific Medical Information Library Europe), medical professionals can search for and download original publications and reviews online, from prominent international peer-reviewed medical scientific journals. Currently, the database contains more than 1000 journals from 28 internationally renowned publishers. S.M.I.L.E. is accessible through www.simid.org and is made possible in part by financial institutions and companies working in the healthcare industry, such as health insurance providers and the pharmaceutical industry.

Investment by the Health Innovation Fund
Recently the Health Innovation Fund I BV has joined SIMID as an investor. This fund is financed from Achmea, OPG, ABN/AMRO and TechnoPartner (the Dutch Ministry of Economic Affairs). "We are proud that this investor has provided us the opportunity to expand our unique product further. By informing medical professionals in Europe about the latest developments within their field, our clients can help them diagnose and treat patients more adequately," comments Boudewijn Gruwel, Director of Marketing & Sales of SIMID.

How does S.M.I.L.E. work?
The medical professional has a customized subscription allowing him free access to the information in S.M.I.L.E. This customized subscription is made possible in part by companies working in the healthcare industry, or financial institutions. "The subscriptions give companies the possibility to provide medical professionals access to the most recent and relevant scientific information," states Boudewijn Gruwel.

S.M.I.L.E. lets users read the latest publications, covering 43 different themes, such as oncology, surgery, cardiology, etc. Users can compile a personal profile and receive automatic alerts when relevant articles become available. The database can also be searched using individual keywords. S.M.I.L.E. is updated daily. The publications containing the listed titles are archived from 2000 on, and all articles can be downloaded as PDF files.

Who is S.M.I.L.E.'s target audience?
The S.M.I.L.E. online database is geared toward health professionals. These might be specialists or general practitioners, but might also be dentists, nurses, or physiotherapists.

About SIMID International B.V.
SIMID stands for the Scientific Institute for Medical Information and Documentation. The goal of SIMID is to provide access to scientific-medical information for health professionals by applying the one-stop-shopping principle. Offering complete publications on a single website creates a unique niche in services to medical professionals and the international healthcare-related industry. Through cooperation with international scientific publishers and the online database S.M.I.L.E., SIMID is the first and only company in Europe able to offer this service to medical professionals. SIMID has branches in the Netherlands and Switzerland. More information can be found at www.simid.org.

About the Health Innovation Fund I BV
The Health Innovation Fund I BV is a venture capital fund established in 2007. It focuses on innovative entrepreneurs providing technological, modernizing solutions and business models for the healthcare industry. Shareholders in this fund are ABN/AMRO, Achmea and OPG. The Health Innovation Fund I BV is administered by Residex, which uses specialized investment funds to offer opportunities to promising and ambitious players in the healthcare sector. More information is available at www.residex.nl.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...